Newsletter | November 17, 2026

11.17.26 -- Reducing Tech Transfer Risk In Autologous CAR T Automation

Mobilizing Science, Partnership, And Capability To Develop A Therapy In 14 Months

Webinar | Andelyn Biosciences

Hear how one family, driven by urgency, partnered with AAV experts to develop a treatment for their daughter’s ultra-rare neurodegenerative disorder, NEDAMSS, in just 14 months.

Freezing Studies For Single-Use Solutions: Therapy Containment/Protection

Video | Charter Medical

Watch part 3 of a four-part series to learn about therapy containment/protection studies, and how they project how a therapy will perform at ultra-low temperatures.

Single-Use Bioreactors Drilled-Hole Sparge Technology

Video | Thermo Fisher Scientific

Uniform bubble size and consistent mass transfer across scales through drilled-hole sparge technology improves oxygen delivery and CO2 stripping in demanding cell culture processes.

 

The Road To Approval: Viral Clearance Strategies For Non-Enveloped Viral Vectors

Webinar | MilliporeSigma

Know the differences between designing a viral clearance study for non-enveloped viral vectors versus those for mAbs or recombinant proteins, and learn how to identify and remove viral contaminants.

Path To IND: AAV Transient Transfection, Producer Cell Line Platforms

Webinar | Lonza

The streamlined AAV transient transfection platform de-risks your path to IND and reduces complexity and timeline for lengthy process and analytical development.

Engineering Universal Blood Cancer Immunotherapy Through CD45 Base Editing

Webinar | MaxCyte, Inc.

Researchers developed base-edited CAR T cells and CD45-edited stem cells to create universal blood cancer immunotherapy, showcasing efficacy while minimizing toxicity using electroporation technology.

Reducing Tech Transfer Risk In Autologous CAR T Automation

Video | 

In this final segment of our Cell & Gene Live, Automating Autologous CAR T Manufacturing: Lessons from Mayo Clinic, expert panelists Anthony DeFusco, M.S., Senior Director of Quality Control for the Center for Regenerative Biotherapeutics; Snigdha Rai, M.S., Senior Director of Biomanufacturing; and Cynthia Wilkins, Ph.D., M.B.A., Senior Director of Process Development and Assistant Professor of Regenerative Medicine, Mayo Clinic focused on quality risks during site transfers, including differences in analytical methods, equipment, reagents, reference materials, and software. 

Connect With Cell & Gene: